Medical/Pharmaceuticals
Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients
* ALA-1000 is the first, three-month slow-release Buprenorphine injection. * Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. * ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treat...
2021-03-10 00:00
1814
Hyperice Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021
Recovery Technology Leader Among Top-Ranked in the Sports Category IRVINE, Calif., March 9, 2021 /PRNewswire/ -- Hyperice, the industry leader in recovery technology and pioneer of percussion, vibration, dynamic air compression and thermal technology, has been named toFast Company's prestigious ...
2021-03-09 22:02
3469
Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study
* Genome and Company expands collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for further clinical combination study of GEN-001 in gastric cancers * Establishment of the efficient "clinical development strategy" for the global immuno-oncology microbiome treatment SEOUL, South Korea,...
2021-03-09 22:00
4383
Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
HONG KONG, March 9, 2021 /PRNewswire/ -- Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico'sChemistry42™ into UCB's internal drug discovery pipeline. UCB's early adoption of Insilico Medicine's proprietary technology will provide UCB's scientists with the...
2021-03-09 22:00
2986
Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.
SUZHOU, China, March 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate an open label, multi-center phase II pivotal clinical study (clinical trial ...
2021-03-09 20:00
3951
Caris' Precision Oncology Alliance Continues to Grow Internationally as it Welcomes Curie Oncology from Singapore
Curie Oncology expands Caris' collaborative network of oncology institutions focused on research into personalized therapies through precision medicine IRVING, Texas, March 9, 2021 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused o...
2021-03-09 19:30
2025
Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021
LONDON, March 9, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of its annual "Drugs to Watch" list, identifying drugs entering the market or launching key indications i...
2021-03-09 16:00
3843
Cytiva and Longitude (a Financial Times company) reveal five major challenges for the industry in new Global Biopharma Resilience Index
- A survey of 1,165 biopharma executives and healthcare policymakers across 20 countries measured ability of industry to respond to global needs in five areas: Supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, and government policy and regulation - There is a strong cor...
2021-03-09 15:00
3397
Nippon Express (Malaysia) Obtains GDP Certification for Domestic Transport Services
TOKYO, March 9, 2021 /PRNewswire/ -- Nippon Express (Malaysia) Sdn, Bhd. (hereinafter, "NE Malaysia"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveThursday, January 14, 2021 for its Kuala Lumpur International A...
2021-03-09 15:00
1916
Yangtze River Pharmaceutical (Group) Co., Ltd. Won the 2021 EFQM Global Award
TAIZHOU, China, March 8, 2021 /PRNewswire/ -- At 19:20 on March 4, 2021 (Beijing time), the results of the 2021 EFQM Global Award were announced. Yangtze River Pharmaceutical (Group) Co., Ltd. fromChina was on the list, which represents that its quality management level has been aligned with that...
2021-03-09 11:19
1864
Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China
HANG ZHOU, China, March 8, 2021 /PRNewswire/ -- On Feb. 26th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as "Winhealth Pharma") signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as "Merz"). The strategic cooperation betwe...
2021-03-09 10:00
3647
Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021
SHANGHAI, March 8, 2021 /PRNewswire/ -- The advanced medical equipment industry chain includes various fields, such as materials, design, components, parts manufacturing, and complete machine manufacturing. Each field may lead to several subdivisions, where high scientific and technological insig...
2021-03-09 09:30
3833
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH
* Oral FASN inhibitor ASC40 shown to meaningfully reduce liver fat with a 50% responder rate * Consistent improvement in biomarkers of liver inflammation as observed in U.S. cohort SHANGHAI, China and SAN MATEO, California, March 9, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly-owned...
2021-03-09 08:30
8314
VolitionRx Limited to Present at Conferences in March 2021
AUSTIN, Texas, March 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer,Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at six conferences inMarch 2021. Duri...
2021-03-09 05:15
6330
Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study
STOCKHOLM, March 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,March 8th , 2021, that its clinical phase IIb study, "BRaVac", in prostate cancer, will be somewhat further delayed as Covid-19 vaccinations are rolled out to the study populatio...
2021-03-09 02:41
1831
AMD Telemed Applauded by Frost & Sullivan for Its Modular Engage N' Solution that Supports Patient Needs by Acuity Level
AMD's unified virtual care framework connects interoperable electronic health records, medical devices, and various engagement models to offer exceptional value to clients SANTA CLARA, Calif., March 9, 2021 /PRNewswire/ -- Based on its recent analysis of the North American virtual care market,Fr...
2021-03-09 01:12
1721
Tergus Lauded by Frost & Sullivan for Its Full-spectrum CRO Services for Therapeutics in Dermatology
With scalable, advanced resource and technology capabilities, Tergus presents pharma companies with exceptional CRO services for all their drug discovery and development requirements SANTA CLARA, Calif., March 8, 2021 /PRNewswire/ -- Based on its recent analysis of the North American contract re...
2021-03-08 22:00
1750
Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer
ST. LOUIS, March 8, 2021 /PRNewswire/ -- Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced that it has entered into an exclusive license and collaboration agreement withShanghai-based...
2021-03-08 22:00
4687
Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results
- Ortho's new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay receive CE Mark - Both tests can aid in identifying individuals with an adaptive immune response (acquired naturally or through vaccination) to SARS-CoV-2 - These new anti-SARS-CoV-2 ant...
2021-03-08 21:00
3715
Changzhou National High-Tech Zone to build 70 new production and service facilities this year
CHANGZHOU, China, March 8, 2021 /PRNewswire/ -- On the morning of February 27th , Changzhou National High-Tech Zone held the groundbreaking ceremony for Phase II of Intersurgical Medical Device (Changzhou) Co., Ltd.'s plant. The ceremony is the first of similar events for zone's 70 planned product...
2021-03-08 17:11
3329
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 318 media titles]
2026-01-23 11:03
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 308 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 306 media titles]
2026-01-23 09:00Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 292 media titles]
2026-01-27 18:00
Most Read
ATOTO CB7 Pro 301% Funded--Head‑Unit AI Console for Wireless CarPlay/Android Auto and Camera‑Smart Driving
2026-01-23 23:00
7952
